Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.

ABSTRACT:

Importance

About 1% of children and adolescents worldwide are affected by plaque psoriasis.

Objective

To evaluate the long-term efficacy and safety of ixekizumab for pediatric patients with moderate to severe psoriasis.

Design, setting, and participants

This multicenter randomized clinical trial (IXORA-PEDS) evaluated pediatric patients with plaque psoriasis. Participants were aged 6 years to younger than 18 years; had moderate to severe psoriasis, which was defined as Psoriasis Area and Severity Index (PASI) of 12 or higher, static Physician's Global Assessment (sPGA) score of 3 or higher, and psoriasis-affected body surface area of 10% or greater at screening and baseline; were candidates for phototherapy or systemic therapy; or had psoriasis that was not adequately

SUBMITTER: Paller AS 

PROVIDER: S-EPMC9008559 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature